XML 37 R27.htm IDEA: XBRL DOCUMENT v3.20.2
EVENTS SUBSEQUENT TO JUNE 30, 2020 (Details)
€ in Millions
1 Months Ended 6 Months Ended 30 Months Ended
Aug. 12, 2020
USD ($)
$ / shares
shares
Dec. 31, 2020
EUR (€)
product
payment
Dec. 31, 2020
USD ($)
product
payment
Dec. 31, 2022
Jul. 01, 2020
USD ($)
Jun. 30, 2020
USD ($)
Dec. 31, 2019
USD ($)
Disclosure of non-adjusting events after reporting period [line items]              
Royalty obligation           $ 500,000 $ 500,000
The "New Drug" | Entry into license agreement | Forecast              
Disclosure of non-adjusting events after reporting period [line items]              
Cost split percentage   70.00% 70.00%        
Payment upon EU marketing approval     $ 2,000,000        
Royalties percentage       30.00%      
Cosmo Pharmaceuticals N.V. | Entry into supply agreement | Forecast              
Disclosure of non-adjusting events after reporting period [line items]              
Number of products | product   3 3        
Payment related to supply agreement | €   € 5.5          
Proceeds related to supply agreement     $ 5,000,000        
Cosmo Pharmaceuticals N.V. | The "New Drug" | Entry into license agreement | Forecast              
Disclosure of non-adjusting events after reporting period [line items]              
Cost split percentage   30.00% 30.00%        
Payment upon signing     $ 7,000,000        
Cosmo Pharmaceuticals N.V. | RHB-204 | Entry into supply agreement | Forecast              
Disclosure of non-adjusting events after reporting period [line items]              
Royalties percentage       15.00%      
Proceeds from milestone payments     $ 7,000,000        
Number of milestone payments | payment   2 2        
Movantik | ADSs | ATM Program | Event subsequent to reporting period              
Disclosure of non-adjusting events after reporting period [line items]              
Number of shares issued | shares 630,486            
Average share price | $ / shares $ 8.09            
Proceeds from issuance of shares $ 5,100,000            
Share issuance expenses $ 100,000            
Movantik | DSI | Event subsequent to reporting period              
Disclosure of non-adjusting events after reporting period [line items]              
Shares issued as consideration         283,387    
Movantik | DSI | December 2021 | Event subsequent to reporting period              
Disclosure of non-adjusting events after reporting period [line items]              
Royalty obligation         $ 5,100,000    
Movantik | DSI | July 2022 | Event subsequent to reporting period              
Disclosure of non-adjusting events after reporting period [line items]              
Royalty obligation         5,000,000    
Movantik | DSI | July 2023 | Event subsequent to reporting period              
Disclosure of non-adjusting events after reporting period [line items]              
Royalty obligation         $ 5,000,000